Newbury expands its portfolio with two ready to launch products

MFN Publicerad: 23 Nov 2022 09:30

Newbury Pharmaceuticals is pleased to announce the expansion of its portfolio with Daptomycin and Linezolid with already granted Marketing Authorizations (MA) in Sweden.

“I am pleased to announce the addition of two new products to our portfolio and in particular that these two products will be available for commercialization already in 2023.” Says Mr. Lars Minor, CEO of Newbury.

Both products are sourced from new partners to Newbury and based on a Distribution and Marketing agreement where Newbury will perform the commercialization in the territory.

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at [email protected] or +46 (0) 40 200 250.

Börskollen

För dig med koll på börsen

Pressmeddelande

Newbury expands its portfolio with two ready to launch products

Bifogade filer

Nyheter om Newbury Pharmaceuticals

Läses av andra just nu

Om aktien Newbury Pharmaceuticals

Senaste nytt